L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...

Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...

PDC Introduces Ident-Alert® IV Port Clips to Help Anesthesiologists Prevent Medication Errors VALENCIA, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- PDC, a global leader of innovative identification and patient safety solutions, announced today the launch of Ident-Alert® IV Port Clips for...

The Professional Development Consortium Awards Language Learning Leader Rosetta Stone with Provider of Training Excellence Accreditation Arlington, VA, March 19, 2018 (GLOBE NEWSWIRE) -- Technology-based learning solutions provider, Rosetta Stone Inc. (NYSE: RST) today announced that it has been awarded full accreditation as a...

Mission Ready's Protect The Force Wins TEEX Award VANCOUVER, BC--(Marketwired - October 27, 2016) - Mission Ready Services Inc. ("Mission Ready" or the "Company") (TSX VENTURE: MRS) is pleased to announce that its subsidiary Protect The Force Inc....